Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer

Anna D. Wagner; Florian Lordick; Heike Grabsch; Masanori Terashima; Mitsumi Terada; Takaki Yoshikawa; Narikazu Boku; Kozo Kataoka; Elizabeth C. Smyth; Murielle Mauer; Karin Haustermans; Markus H. Moehler

doi:10.1016/j.ejca.2019.09.006

Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer

Anna D. Wagner^*, Florian Lordick, Heike Grabsch, Masanori Terashima, Mitsumi Terada, Takaki Yoshikawa, Narikazu Boku, Kozo Kataoka, Elizabeth C. Smyth, Murielle Mauer, Karin Haustermans, Markus H. Moehler

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

The aim of this manuscript is to discuss the viewpoint of the European Organisation for Research and Treatment of Cancer (EORTC) Gastric Cancer Taskforce and Japan Clinical Oncology Group (JCOG) Gastric Cancer Study Group on the current challenges in the multidisciplinary management of stage II-III gastric and gastro-oesophageal junction (GEJ) cancer. We seek to outline how these challenges are addressed in current trials of both groups. Key elements of future trials of EORTC and JCOG in this indication are described, and a joint vision on how multidisciplinary research of gastric and GEJ cancer patients should be organised is outlined. (C) 2019 The Authors. Published by Elsevier Ltd.

Original language	English
Pages (from-to)	67-76
Number of pages	10
Journal	European Journal of Cancer
Volume	124
DOIs	https://doi.org/10.1016/j.ejca.2019.09.006
Publication status	Published - Jan 2020

Keywords

ADENOCARCINOMA
ADJUVANT CHEMOTHERAPY
Adjuvant
CLINICAL-RESEARCH
Chemotherapy
EORTC
EUROPEAN ORGANIZATION
Gastric
Immunotherapy
JCOG
MISMATCH REPAIR DEFICIENCY
OPEN-LABEL
PERIOPERATIVE CHEMOTHERAPY
Perioperative
RANDOMIZED PHASE-II
TRIAL DESIGN
PLUS OXALIPLATIN

Access to Document

10.1016/j.ejca.2019.09.006Licence: CC BY-NC-ND

Cite this

@article{58a4a32049004ede8c181c242e343ff2,

title = "Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer",

abstract = "The aim of this manuscript is to discuss the viewpoint of the European Organisation for Research and Treatment of Cancer (EORTC) Gastric Cancer Taskforce and Japan Clinical Oncology Group (JCOG) Gastric Cancer Study Group on the current challenges in the multidisciplinary management of stage II-III gastric and gastro-oesophageal junction (GEJ) cancer. We seek to outline how these challenges are addressed in current trials of both groups. Key elements of future trials of EORTC and JCOG in this indication are described, and a joint vision on how multidisciplinary research of gastric and GEJ cancer patients should be organised is outlined. (C) 2019 The Authors. Published by Elsevier Ltd.",

keywords = "ADENOCARCINOMA, ADJUVANT CHEMOTHERAPY, Adjuvant, CLINICAL-RESEARCH, Chemotherapy, EORTC, EUROPEAN ORGANIZATION, Gastric, Immunotherapy, JCOG, MISMATCH REPAIR DEFICIENCY, OPEN-LABEL, PERIOPERATIVE CHEMOTHERAPY, Perioperative, RANDOMIZED PHASE-II, TRIAL DESIGN, PLUS OXALIPLATIN",

author = "Wagner, {Anna D.} and Florian Lordick and Heike Grabsch and Masanori Terashima and Mitsumi Terada and Takaki Yoshikawa and Narikazu Boku and Kozo Kataoka and Smyth, {Elizabeth C.} and Murielle Mauer and Karin Haustermans and Moehler, {Markus H.}",

note = "Funding Information: A.D.W. was a consultant or had an advisory role in Lilly , Celgene , BMS , Pfizer , Merck , Servier , Shire and MSD; received travel grants MSD , Ipsen, Sanofi, Abbvie and Astra-Zeneca not related to the present work. F.L. reports grants from MSD , during the conduct of the study; personal fees from Amgen , Astra Zeneca, BioNtech, personal fees and non-financial support from BMS , personal fees from Eli Lilly , Imedex , Infomedica, Iomedico, Medscape, MedUpdate GmbH, MSD , Oncovis GmbH, Springer Nature Group, Astellas and from DKG Web.de not related to the submitted work. H.I.G. had expert advisor role in MSD. M.T. reports personal fees from Taiho, Chugai , Ono, BMS , Yakult , Takeda, Eli Lilly , Pfizer and Daiichi Sankyo, not related to the submitted work. M.T. reported no conflict of interest. T.Y. reports personal fees from Abbott Japan , Eisei, MSD , BMS , Elsevier, Japan, Otsuka Pharmaceutical Factory, ONO, Olimpus, Kyowa Kirin , Covidien , Johnson and Johnson, Daiichi Sankyo, Johnson and Johnson , Terumo , Lilly , Nihon Kayaku and Bristol-Myers Squibb; grants and personal fees from Taiho, Chugai and Yakult and grants from Novartis outside the submitted work. N.B. has received research grant from Taiho, Ono and Bristol-Myers Squibb and honorarium from Taiho, Ono, Bristol-Myers Squibb , Chugai and Eli- Lilly . K.K. has no conflicts of interest. E.C.S. had an advisory role in Astellas, BMS, Celgene, Five Prime Therapeutics, Gritstone Oncology and Servier; received travel grants from Astellas , BMS and Servier . Patent (pending): PCT/SG2018/050514 (Gene expression signature prognostic in resected gastroesophageal cancer) outside the submitted work. M.M. has nothing to disclose. K.H. has nothing to disclose. M.Mo. reports non-financial support from EORTC , during the conduct of the study, personal fees from Falk Foundation , personal fees from Lilly , grants and personal fees from MSD , personal fees from Roche , grants and personal fees from Pfizer , grants and non-financial support from Amgen , grants, personal fees and non-financial support from Bristol-Myers Squibb , grants and personal fees from Merck Serono and personal fees from MCI Group, outside the submitted work. Funding Information: First, is there a role for the integration of radiotherapy in the neoadjuvant component of perioperative chemotherapy? This question is being investigated in the EORTC supported ?TOPGEAR??trial (NCT01924819) [54].A.D.W. was a consultant or had an advisory role in Lilly, Celgene, BMS, Pfizer, Merck, Servier, Shire and MSD; received travel grants MSD, Ipsen, Sanofi, Abbvie and Astra-Zeneca not related to the present work.F.L. reports grants from MSD, during the conduct of the study; personal fees from Amgen, Astra Zeneca, BioNtech, personal fees and non-financial support from BMS, personal fees from Eli Lilly, Imedex, Infomedica, Iomedico, Medscape, MedUpdate GmbH, MSD, Oncovis GmbH, Springer Nature Group, Astellas and from DKG Web.de not related to the submitted work.M.T. reports personal fees from Taiho, Chugai, Ono, BMS, Yakult, Takeda, Eli Lilly, Pfizer and Daiichi Sankyo, not related to the submitted work.T.Y. reports personal fees from Abbott Japan, Eisei, MSD, BMS, Elsevier, Japan, Otsuka Pharmaceutical Factory, ONO, Olimpus, Kyowa Kirin, Covidien, Johnson and Johnson, Daiichi Sankyo, Johnson and Johnson, Terumo, Lilly, Nihon Kayaku and Bristol-Myers Squibb; grants and personal fees from Taiho, Chugai and Yakult and grants from Novartis outside the submitted work.N.B. has received research grant from Taiho, Ono and Bristol-Myers Squibb and honorarium from Taiho, Ono, Bristol-Myers Squibb, Chugai and Eli-Lilly.E.C.S. had an advisory role in Astellas, BMS, Celgene, Five Prime Therapeutics, Gritstone Oncology and Servier; received travel grants from Astellas, BMS and Servier. Patent (pending): PCT/SG2018/050514 (Gene expression signature prognostic in resected gastroesophageal cancer) outside the submitted work.M.Mo. reports non-financial support from EORTC, during the conduct of the study, personal fees from Falk Foundation, personal fees from Lilly, grants and personal fees from MSD, personal fees from Roche, grants and personal fees from Pfizer, grants and non-financial support from Amgen, grants, personal fees and non-financial support from Bristol-Myers Squibb, grants and personal fees from Merck Serono and personal fees from MCI Group, outside the submitted work. Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2020",

month = jan,

doi = "10.1016/j.ejca.2019.09.006",

language = "English",

volume = "124",

pages = "67--76",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

}

TY - JOUR

T1 - Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer

AU - Wagner, Anna D.

AU - Lordick, Florian

AU - Grabsch, Heike

AU - Terashima, Masanori

AU - Terada, Mitsumi

AU - Yoshikawa, Takaki

AU - Boku, Narikazu

AU - Kataoka, Kozo

AU - Smyth, Elizabeth C.

AU - Mauer, Murielle

AU - Haustermans, Karin

AU - Moehler, Markus H.

N1 - Funding Information: A.D.W. was a consultant or had an advisory role in Lilly , Celgene , BMS , Pfizer , Merck , Servier , Shire and MSD; received travel grants MSD , Ipsen, Sanofi, Abbvie and Astra-Zeneca not related to the present work. F.L. reports grants from MSD , during the conduct of the study; personal fees from Amgen , Astra Zeneca, BioNtech, personal fees and non-financial support from BMS , personal fees from Eli Lilly , Imedex , Infomedica, Iomedico, Medscape, MedUpdate GmbH, MSD , Oncovis GmbH, Springer Nature Group, Astellas and from DKG Web.de not related to the submitted work. H.I.G. had expert advisor role in MSD. M.T. reports personal fees from Taiho, Chugai , Ono, BMS , Yakult , Takeda, Eli Lilly , Pfizer and Daiichi Sankyo, not related to the submitted work. M.T. reported no conflict of interest. T.Y. reports personal fees from Abbott Japan , Eisei, MSD , BMS , Elsevier, Japan, Otsuka Pharmaceutical Factory, ONO, Olimpus, Kyowa Kirin , Covidien , Johnson and Johnson, Daiichi Sankyo, Johnson and Johnson , Terumo , Lilly , Nihon Kayaku and Bristol-Myers Squibb; grants and personal fees from Taiho, Chugai and Yakult and grants from Novartis outside the submitted work. N.B. has received research grant from Taiho, Ono and Bristol-Myers Squibb and honorarium from Taiho, Ono, Bristol-Myers Squibb , Chugai and Eli- Lilly . K.K. has no conflicts of interest. E.C.S. had an advisory role in Astellas, BMS, Celgene, Five Prime Therapeutics, Gritstone Oncology and Servier; received travel grants from Astellas , BMS and Servier . Patent (pending): PCT/SG2018/050514 (Gene expression signature prognostic in resected gastroesophageal cancer) outside the submitted work. M.M. has nothing to disclose. K.H. has nothing to disclose. M.Mo. reports non-financial support from EORTC , during the conduct of the study, personal fees from Falk Foundation , personal fees from Lilly , grants and personal fees from MSD , personal fees from Roche , grants and personal fees from Pfizer , grants and non-financial support from Amgen , grants, personal fees and non-financial support from Bristol-Myers Squibb , grants and personal fees from Merck Serono and personal fees from MCI Group, outside the submitted work. Funding Information: First, is there a role for the integration of radiotherapy in the neoadjuvant component of perioperative chemotherapy? This question is being investigated in the EORTC supported ?TOPGEAR??trial (NCT01924819) [54].A.D.W. was a consultant or had an advisory role in Lilly, Celgene, BMS, Pfizer, Merck, Servier, Shire and MSD; received travel grants MSD, Ipsen, Sanofi, Abbvie and Astra-Zeneca not related to the present work.F.L. reports grants from MSD, during the conduct of the study; personal fees from Amgen, Astra Zeneca, BioNtech, personal fees and non-financial support from BMS, personal fees from Eli Lilly, Imedex, Infomedica, Iomedico, Medscape, MedUpdate GmbH, MSD, Oncovis GmbH, Springer Nature Group, Astellas and from DKG Web.de not related to the submitted work.M.T. reports personal fees from Taiho, Chugai, Ono, BMS, Yakult, Takeda, Eli Lilly, Pfizer and Daiichi Sankyo, not related to the submitted work.T.Y. reports personal fees from Abbott Japan, Eisei, MSD, BMS, Elsevier, Japan, Otsuka Pharmaceutical Factory, ONO, Olimpus, Kyowa Kirin, Covidien, Johnson and Johnson, Daiichi Sankyo, Johnson and Johnson, Terumo, Lilly, Nihon Kayaku and Bristol-Myers Squibb; grants and personal fees from Taiho, Chugai and Yakult and grants from Novartis outside the submitted work.N.B. has received research grant from Taiho, Ono and Bristol-Myers Squibb and honorarium from Taiho, Ono, Bristol-Myers Squibb, Chugai and Eli-Lilly.E.C.S. had an advisory role in Astellas, BMS, Celgene, Five Prime Therapeutics, Gritstone Oncology and Servier; received travel grants from Astellas, BMS and Servier. Patent (pending): PCT/SG2018/050514 (Gene expression signature prognostic in resected gastroesophageal cancer) outside the submitted work.M.Mo. reports non-financial support from EORTC, during the conduct of the study, personal fees from Falk Foundation, personal fees from Lilly, grants and personal fees from MSD, personal fees from Roche, grants and personal fees from Pfizer, grants and non-financial support from Amgen, grants, personal fees and non-financial support from Bristol-Myers Squibb, grants and personal fees from Merck Serono and personal fees from MCI Group, outside the submitted work. Publisher Copyright: © 2019 The Authors

PY - 2020/1

Y1 - 2020/1

N2 - The aim of this manuscript is to discuss the viewpoint of the European Organisation for Research and Treatment of Cancer (EORTC) Gastric Cancer Taskforce and Japan Clinical Oncology Group (JCOG) Gastric Cancer Study Group on the current challenges in the multidisciplinary management of stage II-III gastric and gastro-oesophageal junction (GEJ) cancer. We seek to outline how these challenges are addressed in current trials of both groups. Key elements of future trials of EORTC and JCOG in this indication are described, and a joint vision on how multidisciplinary research of gastric and GEJ cancer patients should be organised is outlined. (C) 2019 The Authors. Published by Elsevier Ltd.

AB - The aim of this manuscript is to discuss the viewpoint of the European Organisation for Research and Treatment of Cancer (EORTC) Gastric Cancer Taskforce and Japan Clinical Oncology Group (JCOG) Gastric Cancer Study Group on the current challenges in the multidisciplinary management of stage II-III gastric and gastro-oesophageal junction (GEJ) cancer. We seek to outline how these challenges are addressed in current trials of both groups. Key elements of future trials of EORTC and JCOG in this indication are described, and a joint vision on how multidisciplinary research of gastric and GEJ cancer patients should be organised is outlined. (C) 2019 The Authors. Published by Elsevier Ltd.

KW - ADENOCARCINOMA

KW - ADJUVANT CHEMOTHERAPY

KW - Adjuvant

KW - CLINICAL-RESEARCH

KW - Chemotherapy

KW - EORTC

KW - EUROPEAN ORGANIZATION

KW - Gastric

KW - Immunotherapy

KW - JCOG

KW - MISMATCH REPAIR DEFICIENCY

KW - OPEN-LABEL

KW - PERIOPERATIVE CHEMOTHERAPY

KW - Perioperative

KW - RANDOMIZED PHASE-II

KW - TRIAL DESIGN

KW - PLUS OXALIPLATIN

U2 - 10.1016/j.ejca.2019.09.006

DO - 10.1016/j.ejca.2019.09.006

M3 - (Systematic) Review article

C2 - 31759294

SN - 0959-8049

VL - 124

SP - 67

EP - 76

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -